[go: up one dir, main page]

CY1119410T1 - Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) - Google Patents

Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)

Info

Publication number
CY1119410T1
CY1119410T1 CY20171101040T CY171101040T CY1119410T1 CY 1119410 T1 CY1119410 T1 CY 1119410T1 CY 20171101040 T CY20171101040 T CY 20171101040T CY 171101040 T CY171101040 T CY 171101040T CY 1119410 T1 CY1119410 T1 CY 1119410T1
Authority
CY
Cyprus
Prior art keywords
tfpi
monoclonal antibodies
antibodies against
inhibitor
antibodies
Prior art date
Application number
CY20171101040T
Other languages
English (en)
Inventor
Peter Scholz
Zhuozhi Wang
Junliang Pan
Joanna Grudzinska
Christian Votsmeier
Jan Tebbe
Jörg BIRKENFELD
Nina Wobst
Simone BRÜCKNER
Susanne Steinig
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119410(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CY1119410T1 publication Critical patent/CY1119410T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Filtering Materials (AREA)

Abstract

Απομονωμένα μονόκλωνα αντισώματα που δεσμεύουν τον αναστολέα της οδού του ιστικού παράγοντα ανθρώπου (TFPI). Απομονωμένα, επίσης, μόρια νουκλεϊκού οξέος που κωδικοποιούν μονοκλωνικά αντισώματα που δεσμεύουν τον TFPI. Παρέχονται, επίσης, φαρμακευτικές συνθέσεις που περιλαμβάνουν τα αντι-TFPI μονοκλωνικά αντισώματα και μέθοδοι θεραπείας ελλείψεων ή ελαττωμάτων στην πήξη με χορήγηση των αντισωμάτων. Παρέχονται, επίσης, μέθοδοι παραγωγής των αντισωμάτων.
CY20171101040T 2010-03-01 2017-10-05 Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) CY1119410T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01
PCT/US2011/026766 WO2011109452A1 (en) 2010-03-01 2011-03-01 Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)

Publications (1)

Publication Number Publication Date
CY1119410T1 true CY1119410T1 (el) 2018-03-07

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101040T CY1119410T1 (el) 2010-03-01 2017-10-05 Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY20201100019T CY1122476T1 (el) 2010-03-01 2020-01-09 Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100019T CY1122476T1 (el) 2010-03-01 2020-01-09 Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)

Country Status (37)

Country Link
US (3) US9309324B2 (el)
EP (2) EP2542257B1 (el)
JP (4) JP6025570B2 (el)
KR (4) KR101903931B1 (el)
CN (5) CN106188301A (el)
AU (1) AU2011223710B2 (el)
BR (1) BR112012022258A2 (el)
CA (3) CA2976671C (el)
CL (2) CL2012002415A1 (el)
CO (1) CO6620068A2 (el)
CR (1) CR20120453A (el)
CU (1) CU23982B1 (el)
CY (2) CY1119410T1 (el)
DK (2) DK3345615T3 (el)
DO (1) DOP2012000239A (el)
EA (2) EA201892184A1 (el)
EC (2) ECSP12012134A (el)
ES (2) ES2642512T3 (el)
GT (1) GT201200252A (el)
HK (2) HK1232232A1 (el)
HR (2) HRP20171472T1 (el)
HU (2) HUE036655T2 (el)
IL (3) IL221551B (el)
LT (2) LT3345615T (el)
ME (2) ME03578B (el)
MX (2) MX2012010198A (el)
MY (1) MY174760A (el)
NZ (2) NZ602115A (el)
PE (1) PE20160538A1 (el)
PH (4) PH12012501742A1 (el)
PL (2) PL2542257T3 (el)
PT (2) PT3345615T (el)
RS (2) RS59830B1 (el)
SG (3) SG10201502587SA (el)
SI (2) SI3345615T1 (el)
SM (1) SMT201700454T1 (el)
WO (1) WO2011109452A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011006501A (es) 2008-12-22 2011-07-12 Novo Nordisk As Anticuerpos contra inhibidor de la via de factor de tejido.
EA201892184A1 (ru) * 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
PT2694544T (pt) * 2011-04-01 2019-04-02 Bayer Healthcare Llc Anticorpos monoclonais contra inibidor da via do fator tecidual (tfpi)
JP6283017B2 (ja) * 2012-03-30 2018-02-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ プロテアーゼ制御抗体
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RS56814B1 (sr) * 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
UY35459A (es) * 2013-03-15 2014-10-31 Bayer Healthcare Llc Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
AU2016307967C9 (en) * 2015-08-19 2025-02-20 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
KR20240135884A (ko) * 2018-10-11 2024-09-12 화이자 인코포레이티드 Tfpi 길항제의 투여량 섭생법
KR102692277B1 (ko) * 2019-03-11 2024-08-05 현대자동차주식회사 상용 전기차용 모터 마운트
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
AU2021378707A1 (en) * 2020-11-13 2023-06-01 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5589167A (en) 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
ATE251893T1 (de) 1996-01-25 2003-11-15 Schering Ag Verbesserte kontrastmittenlösungen für die intravasale anwendung
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
ES2513043T3 (es) 1997-03-26 2014-10-24 Imperial Innovations Limited Proteína de fusión anticoagulante anclada a membrana de la célula
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2002505871A (ja) 1998-03-12 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３１個のヒト分泌タンパク質
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US7163671B2 (en) 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
IL152130A0 (en) 2000-04-07 2003-05-29 Ellis L Kline Methods and compositions for treating neoplasms
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
EP1930024A3 (en) 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF solution formulations having long-term stability
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
EP1379549A2 (fr) 2001-02-07 2004-01-14 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
CA2387401C (en) 2001-05-21 2004-10-12 Ecopia Biosciences Inc. Compositions, methods and systems for the production of enediynes
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
KR20050036852A (ko) * 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
BR0213298A (pt) 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003037172A2 (en) 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1461353A4 (en) 2001-11-29 2006-05-03 Wyeth Corp OPEN READING FRAMES (ORF) OF BACTERIUM ALLOIOCOCCUS OTITIDIS ENCODING ANTIGENIC POLYPEPTIDES, IMUNOGENIC COMPOSITIONS, AND USES THEREOF
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
AU2003225535A1 (en) 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
DK1478394T3 (da) 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
US20060068386A1 (en) 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
PT1556083E (pt) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
US20050058649A1 (en) 2002-12-02 2005-03-17 Landes Gregory M. Antibodies directed to phospholipase A2 and uses thereof
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2853593T3 (en) 2003-03-07 2018-01-08 Dsm Ip Assets Bv Hydrolases, nucleic acids encoding them, and processes for their preparation and use
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
UA115960C2 (uk) 2003-07-15 2018-01-25 Емджен, Інк., Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf)
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005055930A2 (en) 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
EP2284184A3 (en) 2004-01-09 2011-05-18 Novozymes, Inc. Bacillus YvmA inactivation
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
ES2426725T3 (es) 2004-05-27 2013-10-24 Crucell Holland B.V. Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia
EP1755677A4 (en) 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
KR101017301B1 (ko) 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
DK1848744T3 (da) 2005-01-27 2012-03-19 Novimmune Sa Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006207901A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
EP2194140A2 (en) 2005-03-02 2010-06-09 Metanomics GmbH Process for the production of fine chemicals
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
JP2006249082A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 低減レベルの内毒素を有する抗ｍ−ｃｓｆ抗体組成物
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
EP2264162A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
BRPI0614100A2 (pt) 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
US20070224627A1 (en) 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
MX2008015852A (es) 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
RU2009111138A (ru) 2006-10-12 2010-11-20 Вайет (Us) Способы и композиции с уменьшенной опалесценцией
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP3002298B1 (en) * 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
JP2011507922A (ja) 2007-12-28 2011-03-10 バイオインヴェント インターナショナル アーベー 配合物
CN101970494B (zh) 2008-02-20 2015-01-21 G2炎症私人有限公司 人源化抗-C5aR抗体
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
TR201802935T4 (tr) 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
JP2012510468A (ja) 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SI2379096T1 (sl) 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
MX2011006501A (es) 2008-12-22 2011-07-12 Novo Nordisk As Anticuerpos contra inhibidor de la via de factor de tejido.
CN102300876A (zh) 2008-12-22 2011-12-28 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂(tfpi)的抗体
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2442798A4 (en) 2009-06-18 2013-03-13 Wyeth Llc LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
PL3725330T3 (pl) 2009-09-03 2025-12-08 Ablynx N.V. Stabilne formulacje polipeptydów i ich zastosowania
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
EA201892184A1 (ru) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
CA2793465C (en) 2010-03-19 2022-06-14 Baxter International Inc. Tfpi inhibitors and methods of use
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
EP2673364A1 (en) 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PT2694544T (pt) 2011-04-01 2019-04-02 Bayer Healthcare Llc Anticorpos monoclonais contra inibidor da via do fator tecidual (tfpi)
WO2013142153A2 (en) 2012-03-22 2013-09-26 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
RS56814B1 (sr) 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
JP6660957B2 (ja) 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
AU2016307967C9 (en) 2015-08-19 2025-02-20 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof

Also Published As

Publication number Publication date
CN105001335A (zh) 2015-10-28
KR20170137218A (ko) 2017-12-12
ECSP19025350A (es) 2019-04-30
LT2542257T (lt) 2017-11-27
MX2012010198A (es) 2012-10-03
SMT201700454T1 (it) 2018-01-11
ES2642512T3 (es) 2017-11-16
CU23982B1 (es) 2014-03-26
PH12012501742A1 (en) 2022-03-21
GT201200252A (es) 2014-04-03
DK2542257T3 (en) 2017-10-16
MX354743B (es) 2018-03-16
US20120108796A1 (en) 2012-05-03
EA032189B1 (ru) 2019-04-30
SG10201502587SA (en) 2015-06-29
LT3345615T (lt) 2020-02-10
EA032189B9 (ru) 2019-09-30
JP6475679B2 (ja) 2019-02-27
ECSP12012134A (es) 2012-09-28
PE20160538A1 (es) 2016-05-19
EP2542257A1 (en) 2013-01-09
CA2791685A1 (en) 2011-09-09
KR20180091116A (ko) 2018-08-14
JP2020115868A (ja) 2020-08-06
HK1254947A1 (zh) 2019-08-02
DK3345615T3 (da) 2020-01-20
NZ702494A (en) 2016-09-30
HUE036655T2 (hu) 2018-07-30
IL277391A (en) 2020-11-30
IL221551B (en) 2019-08-29
MY174760A (en) 2020-05-13
US20120329996A1 (en) 2012-12-27
EP3345615B1 (en) 2019-10-16
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
CL2017003218A1 (es) 2018-06-08
NZ602115A (en) 2014-12-24
HK1232232A1 (zh) 2018-01-05
ES2765418T3 (es) 2020-06-09
CA2976671A1 (en) 2011-09-09
US8481030B2 (en) 2013-07-09
CN105001335B (zh) 2019-10-25
IL262444A (en) 2018-12-31
SI2542257T1 (en) 2018-01-31
BR112012022258A2 (pt) 2016-10-25
CL2012002415A1 (es) 2013-08-23
PH12018500641A1 (en) 2019-07-29
PT2542257T (pt) 2017-10-09
EP3345615A1 (en) 2018-07-11
PH12018500640A1 (en) 2019-07-29
HRP20192295T1 (hr) 2020-03-20
AU2011223710B2 (en) 2016-04-14
PL3345615T3 (pl) 2020-07-13
HUE047173T2 (hu) 2020-04-28
CU20120126A7 (es) 2013-01-30
EP2542257B1 (en) 2017-07-05
KR101807894B1 (ko) 2017-12-12
SG10201903166PA (en) 2019-05-30
ME02894B (me) 2018-04-20
US9309324B2 (en) 2016-04-12
RS56409B1 (sr) 2018-01-31
SG183443A1 (en) 2012-09-27
EA201892184A1 (ru) 2019-03-29
CA2791685C (en) 2019-07-23
CN102939098B (zh) 2016-08-03
JP2019089807A (ja) 2019-06-13
CN110835373A (zh) 2020-02-25
PT3345615T (pt) 2020-01-17
EA201290849A1 (ru) 2013-05-30
JP6025570B2 (ja) 2016-11-16
CN107987166A (zh) 2018-05-04
USRE47150E1 (en) 2018-12-04
KR20130004586A (ko) 2013-01-11
JP2013520996A (ja) 2013-06-10
WO2011109452A1 (en) 2011-09-09
PH12018500639A1 (en) 2019-07-29
DOP2012000239A (es) 2013-08-15
KR101903931B1 (ko) 2018-10-02
PL2542257T3 (pl) 2018-01-31
SI3345615T1 (sl) 2020-03-31
HRP20171472T1 (hr) 2017-12-01
CY1122476T1 (el) 2021-01-27
CR20120453A (es) 2013-02-27
JP2017035100A (ja) 2017-02-16
KR20190047135A (ko) 2019-05-07
ME03578B (me) 2020-07-20
CN102939098A (zh) 2013-02-20
AU2011223710A1 (en) 2012-09-20
CA2976671C (en) 2021-01-12
IL262444B (en) 2021-01-31
JP6684369B2 (ja) 2020-04-22
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
CO6620068A2 (es) 2013-02-15
EP2542257A4 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1123739T1 (el) Αντισωματα anti-cd38
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CY1115984T1 (el) Νεες amino αζαετεροκυκλικες καρβοξαμιδες
CY1115204T1 (el) Παραγωγα νεων υπεροξειδιων, μεθοδος παρασκευης τους και η χρηση τους στην ανθρωπινη ιατρικη καθως επισης και στα καλλυντικα για τη θεραπεια ή την προληψη της ακμης